Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5809985 | 1.00 | — | — | |
| Water SCHEMBL11750618 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL1697235 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL9333419 | 1.00 | — | — | |
| Water SCHEMBL7032487 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL8140555 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL660657 | 1.00 | — | — | |
| Water SCHEMBL22581621 | 0.95 | — | — | |
| Water SCHEMBL22581609 | 0.95 | — | — | |
| Water SCHEMBL10342957 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604274-A | Geopodaxine preparation | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119546302-A | For the treatment of bacterial prostate Geopodaxine for treating adenosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-12227481-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | EXELIXIS, INC. (US) | 2025-02-18 | — | — | US | claimed |
| WO-2024028263-A1 | GEPOTIDACIN FORMULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-08 | — | — | WO | claimed |
| EP-4316463-A1 | NOVEL FORMULATION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| CN-111065621-B | New method for preparing antibody-drug conjugate | 第一三共株式会社 | 2024-01-26 | — | — | CN | claimed |
| US-20240010621-A1 | CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | EXELIXIS, INC. | 2024-01-11 | — | — | US | claimed |
| EP-4288035-A1 | ORAL SOLID DOSE FORMULATIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-12-13 | — | — | EP | claimed |
| CN-116887818-A | Oral solid dosage formulation | 葛兰素史克知识产权发展有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20230167113-A1 | CRYSTALLINE FORMS OF GEPOTIDACIN | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | claimed |
| CN-111051330-A | Improved preparation method of antibody-drug conjugate | 第一三共株式会社 | 2020-04-21 | — | — | CN | claimed |
| EP-0918772-B1 | MESYLATE DIHYDRATE SALTS OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ONE (=ZIPRASIDONE), ITS PREPARATION AND ITS USE AS DOPAMINE D2 ANTAGONIST | PFIZER (US) | 2004-10-06 | — | — | EP | claimed |
| CN-1091769-C | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzi sothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one | PFIZER (US) | 2002-10-02 | — | — | CN | claimed |
| CN-1332167-A | Eprosartan dihydrate and its prep. | SMITHKLINE BEECHEM CORP (US) | 2002-01-23 | — | — | CN | claimed |
| US-6245765-B1 | PSYCHOLOGICAL DISORDERS | PFIZER INC | 2001-06-12 | — | — | US | claimed |
| EP-0918772-A1 | MESYLATE DIHYDRATE SALTS OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ONE (=ZIPRASIDONE), ITS PREPARATION AND ITS USE AS DOPAMINE D2 ANTAGONIST | PFIZER INC. (US) | 1999-06-02 | — | — | EP | claimed |
| CN-1216991-A | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzi sothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one | PFIZER (US) | 1999-05-19 | — | — | CN | claimed |
| CN-1214682-A | EPROSARATAN dihydrate and preparation and formulation method thereof | SMITHKLINE BEECHAM CORP (US) | 1999-04-21 | — | — | CN | claimed |
| WO-1997042191-A1 | MESYLATE DIHYDRATE SALTS OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ONE (=ZIPRASIDONE), ITS PREPARATION AND ITS USE AS DOPAMINE D2 ANTAGONIST | PFIZER INC. (US) | 1997-11-13 | — | — | WO | claimed |
| CN-1091429-A | Lactam derivatives | GLAXO GROUP LTD (GB) | 1994-08-31 | — | — | CN | claimed |